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Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic interstitial lung disease with a relentlessly progressive course and fatal
outcome. Guidelines summarizing the current evidence and providing evidence-based recommendations for the
treatment of rare diseases such as IPF are important since individual physicians often have limited experience.
Nevertheless, the available evidence is often scarce and, therefore, evidence-based recommendations are prone to being
vague or with low confidence, thus creating uncertainty instead of guidance. Moreover, the effect of guidelines
themselves on clinical practice has not been sufficiently evaluated. On the other hand, expert opinion may be biased
and lead to the misinterpretation of evidence, resulting in misleading recommendations and a potential harm to
patients. This editorial focuses on the advantages and disadvantages of evidence-based guidelines and professional
experience in the context of a rare disease such as IPF and tries to assess the optimum combination of both approaches.
Please see related commentary articles: http://dx.doi.org/10.1186/s12916-016-0562-1 and http://dx.doi.org/10.1186/
s12916-016-0563-0
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Guidelines and evidence-based medicine: the
downfall of the Holy Grail
Over 20 years ago, evidence-based medicine began to
replace medical practices based on tradition, anecdotes,
and theoretical reasoning through empirical evidence from
clinical trials [1]. The foundations of evidence-based
medicine rely on the development and implementation
of evidence-based guidelines. Ideally, the knowledge
obtained from high-quality clinical trials should translate
directly into patient management in daily practice, thus
improving patient care and replacing unproven clinical
approaches. Unfortunately, this courageous concept has
several inherent problems. Given the extremely high
cost of good-quality clinical trials, these are mostly per-
formed under the direction of the pharmaceutical industry,
thus targeting their needs for the approval of new therapies
rather than the often differing needs of clinical practice [1].
Consequently, many challenges faced in daily patient care
have never been nor will ever be addressed through an
evidence-based approach. Moreover, guidelines based solely
on evidence from clinical trials are prone to overestimated,
standardized diagnostic procedures in accordance with
clinical trial needs, thus leading to a management-centered
rather than a patient-centered approach [2]. Inflexible rules
from evidence-based guidelines also exclude a significant
proportion of the patient population from an appropriate
clinical diagnosis and potentially disenfranchise them from
available therapies, leaving patients and physicians in a
diagnostic and therapeutic void and increasing diagnostic
and therapeutic uncertainty [2]. Finally, complex diseases
and multimorbidity are difficult to address with evidence-
based guidelines, since clinical trials tend to exclude
complexity for evident reasons. Linked to this is the
challenge of the methodology of guideline development.
Experience with the Grading of Recommendations,
Assessment, Development and Evaluations (GRADE)
methodology reveals that the recommendations are some-
times insufficient to allow an appropriate differentiation.
Moreover, the wording is often awkward, using formulas
which make it difficult for physicians to fully understand
the meaning of a recommendation [3, 4]. Conversely,
expert opinion based on clinical experience may be able
to provide clear guidance even in the absence of formal
evidence. Regrettably, in the past, opinion hegemony of
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powerful personalities or groups, as well as supposed
“evidence-based medicine”, were the source of mis- or
over-interpretation of the available evidence eventually
leading to biased, potentially harmful recommendations.
The above issues are of particular importance in a rare
disease such as idiopathic pulmonary fibrosis (IPF), where
individual physicians often have limited experience and
rely on the available guidance.
IPF treatment guideline development is an archetypal
example to examine the positive and negative impacts of
evidence-based guidelines. The 2011 ATS/ERS/JRS/ALAT
guideline is an excellent summary of the available evidence
and provides and implements a new definition of IPF [3].
By upgrading the utility of high-resolution computed tom-
ography (HRCT) and defining the radiological usual inter-
stitial pneumonia pattern, the guideline also significantly
changed the diagnostic process, eliminating the need for a
surgical lung biopsy for patients with a definite usual
interstitial pneumonia pattern on HRCT [5]. Nevertheless,
interpretation of HRCT is often not unequivocal, and
thus diagnostic uncertainty has increased in many patients
[2, 5]. A surgical lung biopsy is performed to rule out
uncertainty; however, it is not feasible for a significant
number of patients with IPF due to disease severity, co-
morbidities, frailty, or cost [5]. The multidisciplinary
discussion proposed as the gold standard in the guideline
leads to a choice of various diagnostic probabilities –
definite, probable, and possible; however, the therapeutic
implications are defined only for the definite diagnostic
category of IPF. The most recent update of the IPF guide-
line focused on disease treatment and recommended the
two available drugs, nintedanib and pirfenidone, for the
majority of IPF patients [6]. However, evidence-based IPF
guidelines do not address the treatment of patients with a
“probable” or “possible” IPF diagnosis [6]. In this context,
it is also imperative to comprehend that guidelines them-
selves are an intervention in clinical practice, with both
potentially beneficial and harmful consequences. Despite
this, the net effect of guidelines after their implementation
remains to be addressed.
The art of clinical decision making
As indicated by Rochwerg et al. [7], evidence-based
guidelines provide a comprehensive summary of the
available evidence and a transparent process leading to
recommendations which are not biased by personal
experiences or opinions of individual experts. The strength
of the GRADE methodology used in this process lies on
the systematic and pragmatic literature search which leads
to an unbiased overview of the available evidence in a
given topic. Its shortcoming is the fact that the meth-
odology tends to exclude any clinical experience and
common sense not supported by formal evidence from
well-designed clinical trials, as succinctly discussed by
Wells [8]. This approach eventually leads to recommenda-
tions which lack practicability, as exemplified in the diag-
nostic algorithm of the IPF guideline, which foresees a
surgical lung biopsy for patients with a non-informational
HRCT, but yet this cannot be performed in a large portion
of these patients due to disease severity, comorbidities, or
cost. Consequently, according to this guideline, a significant
number of patients is left without a diagnosis or treatment
[3, 7]. This differentiation has gained significance since the
recent approval of nintedanib and pirfenidone [6], since the
issue of whether these drugs should also be used in prob-
able and possible IPF remains unresolved. While possible
IPF patients have been included in the INPULSIS trials with
nintedanib, only definite IPF patients were allowed in the
ASCEND trail with pirfenidone [7–10]. However, neither of
these studies has led to a definite solution. In the absence
of clinical trials addressing this question, an evidence-based
recommendation will not be possible; nevertheless, for
clinical guidance, a practical recommendation is highly
desirable. Therefore, complementing evidence-based
recommendations with clinical expertise and advice in
areas with little or no evidence should be considered in
order to provide practical guidance. There is no doubt that
the 2011 evidence-based IPF guidelines [3] are appropriate
for the diagnosis of approximately 70 % of IPF cases; how-
ever, there is no guidance regarding the diagnosis and
treatment of the remaining 30 % for whom the suggested
alternative diagnostic test is not feasible. Thus, rigid inter-
pretation of guidelines may be deleterious for patients by
excluding them from appropriate diagnosis and therapy.
The evidence-based guideline approach overemphasizes
standardized diagnostic tools and neglects the art of clin-
ical decision making. The latter takes into consideration
all available information on an individual patient, includ-
ing the clinical behavior of the disease and response to
previous therapies, and is of paramount importance
for those patients who fall beyond the evidence base.
A multidisciplinary discussion, including pneumologists,
radiologists, and pathologists, to decide on an individual
patient basis, as proposed in the guideline, appears to be
the optimal setting in which to practice this art of clinical
decision making.
Conclusions
Evidence-based guidelines summarize the available evi-
dence using a comprehensive literature research approach
and provide unbiased recommendations reflecting this evi-
dence. However, this emphasis on methodology eventually
results in a lack of practicability and guidance in areas with
a dearth of evidence. The empirical approach based on ex-
pert advice can provide guidance, especially in areas with
little or no formal evidence, but is vulnerable to biased rec-
ommendations. Thus, both approaches may adversely affect
patients. A synthesis of these potentially complementary
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approaches seems appropriate to provide optimal guidance
in the treatment of all patients.
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